Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia
Open Access
- 1 November 2012
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 22 (5), 656-667
- https://doi.org/10.1016/j.ccr.2012.08.027
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemiaLeukemia Research, 2011
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensationTrends in Biochemical Sciences, 2011
- Crystal Structures of Human TBC1D1 and TBC1D4 (AS160) RabGTPase-activating Protein (RabGAP) Domains Reveal Critical Elements for GLUT4 TranslocationJournal of Biological Chemistry, 2011
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- Pre–B cell receptor–mediated cell cycle arrest in Philadelphia chromosome–positive acute lymphoblastic leukemia requires IKAROS functionThe Journal of Experimental Medicine, 2009
- RNAi screen for rapid therapeutic target identification in leukemia patientsProceedings of the National Academy of Sciences, 2009
- Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5aProceedings of the National Academy of Sciences, 2008
- RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemiaBlood, 2008
- The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibProceedings of the National Academy of Sciences, 2007